Documentation

Press release

Datesort descending Press release
08/03/2018 - 17:45 CET Inventiva to present at six investor conferences in March 2018
13/03/2018 - 17:45 CET Inventiva’s paper on the discovery and synthesis of its panPPAR agonist lanifibranor accepted and published in the Journal of Medicinal Chemistry of the American Chemical Society
28/03/2018 - 17:45 CET Lanifibranor carcinogenicity studies: Progressing as planned and interim results in rats indicate no compound related urinary bladder tumors
03/04/2018 - 17:45 CET Inventiva Announces a U.S. Phase II Investigator-Initiated Study with Lanifibranor on Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes
16/04/2018 - 12:55 CET Publication of the 2017 registration document (only in French)
02/05/2018 - 18:51 CET Information relative au nombre total de droits de vote et d’actions composant le capital social au 30 avril 2018 (in french only)
28/05/2018 - 18:04 CET Dr Lucy Lu is appointed to the Inventiva Board of Directors
29/05/2018 - 18:02 CET Résultat des votes de l’Assemblée Générale du 28 mai 2018 (french only)
30/05/2018 - 17:45 CET Inventiva to Present at the Jefferies 2018 Global Healthcare Conference
11/06/2018 - 17:45 CET Inventiva to Present at the 2018 JMP Securities Life Sciences Conference
20/06/2018 - 17:45 CET FDA Approval of an Investigator Initiated IND Application to Conduct Phase II Study of Lanifibranor in Type 2 Diabetic Patients with Non-Alcoholic Fatty Liver Disease
10/07/2018 - 17:45 CET Inventiva Announces Positive DSMB Reviews in both NASH and Systemic Sclerosis Phase IIb Trials with Lanifibranor
26/07/2018 - 17:45 CET Inventiva Announces Poster Presentation on a Promising Biomarker for MPS VI at the 15th International Symposium on MPS and Related Diseases
01/08/2018 - 17:45 CET Inventiva to Present the Latest Findings in its RORγ program at the 256th National Meeting of the American Chemical Society
13/08/2018 - 17:45 CET Inventiva’s lanifibranor found to have good safety profile following first assessment of carcinogenicity studies’ results
22/08/2018 - 17:45 CET Inventiva announces that it has been informed of the modification of the call option agreement concluded by BVF Partners L.P.
29/08/2018 - 17:45 CET Inventiva to Present at the H.C. Wainwright 20th Annual Global Investment Conference
30/08/2018 - 17:45 CET Inventiva advances in the development of lanifibranor with the achievement of three key milestones

Pages